Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs)
$66.18
neg -0.74
-1.11%
Today's Range: 64.05 - 67.49 | VRTX Avg Daily Volume: 1,632,800
Last Update: 04/24/14 - 4:00 PM EDT
Volume: 1,203,086
YTD Performance: -9.93%
Open: $66.96
Previous Close: $66.92
52 Week Range: $58.06 - $89.96
Oustanding Shares: 235,771,942
Market Cap: 16,126,490,375
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 12 12 12
Moderate Buy 0 1 1 1
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.63 1.61 1.61 1.61
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -39.90
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-39.90 0.00 29.23
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-20.17% -19.89% 35.55%
GROWTH 12 Mo 3 Yr CAGR
Revenue -20.60 7.45 1.02
Net Income 0.00 -0.09 0.00
EPS 0.00 -0.47 0.00
Earnings for VRTX:
EBITDA -0.15B
Revenue 1.21B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $-0.76 $-0.64 $-2.22 $0.75
Number of Analysts 5 5 9 7
High Estimate $-0.66 $-0.56 $-1.55 $1.86
Low Estimate $-0.88 $-0.75 $-2.55 $-1.16
Prior Year $-0.12 $-0.22 $-1.47 $-2.22
Growth Rate (Year over Year) -533.33% -190.91% -51.02% 133.78%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Stocks for the Noncommittal Real Money Pro($)

You don't need much conviction to trade these two names.
These types of companies are winners today.
Bullish
Jan 06, 2014 | 7:26 AM EST
VRTX was upgraded to Buy from Neutral, UBS said. Driven by confidence that lumicaftor-ivacaftor combination will be successful in 2014 ...
Bearish
Oct 30, 2013 | 7:59 AM EDT
Shares of VRTX now seen reaching $78, according to Credit Suisse. Estimates also reduced, given lower Incivek sales. Neutral rating.&nb...
Bullish
Aug 22, 2013 | 7:13 AM EDT
Coverage of VRTX was started with an Outperform rating, Oppenheimer said. $105 price target. Cystic Fibrosis treatments can continue to...
Bullish
Jul 30, 2013 | 8:18 AM EDT
VRTX earnings estimates reflect an increased outlook for Kalydeco, said UBS. Price target is now $84.

Early-Morning Market Look Real Money Pro($)

Let's start by taking a peek at the overnight and early-morning price action of the major asset classes.
Bearish
Jul 26, 2013 | 8:07 AM EDT
Shares of VRTX were downgraded to a Neutral rating and given a $83 price target based on the safety concerns for VX-135, UBS said.
Stick with solid investing precepts.
We are seeing some hot pockets of momentum.

Columnist Conversations

CH Robinson has had a higher gap opening the last four days in a row. Boy, someone really wants to own it (see...
The wicked, whipsaw action following FB's earnings release last evening warns me the stock likely has ended a ...
Lang:
This stock has been a dog for years, but its ears are perking here lately, and today has my eye. The May call...
Good afternoon! Oil has taken a swift turn this week and is showing further weakness ahead. Here is a quick up...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.